Wouldn't you think there are multiple local companies that could handle the production? We need lots of vaccine in a short time. A few companies can't to that. And AstraZenecas current price for the vaccine doesn't need to be the price after the pandemic when corona shots are maybe as common as flu shots. The took the results of public funded research, can produce a vaccine without risk of loss and and chance of high profit in the future. And Oxfords insistence on low manufacturing costs, doesn't make it affordable if the IP is hold by a single company. It just raises the profit margin. Oxford should have insisted on a maximum markup to the manufacturing price.